Insider Transaction: Stock Option Grant at CRISPR Therapeutics AG

Sandesh Mahatme, a director at CRISPR Therapeutics AG (CRSP), was granted 13,000 stock options on June 5, 2026. These options have an exercise price of $51.84 and will vest in 12 equal monthly installments starting June 30, 2026, contingent upon continued service. The options are exercisable until June 5, 2036. Following this transaction, Mahatme holds 13,000 shares/options. The filing also notes that the options will fully vest by the earlier of the one-year anniversary of the grant date or the 2027 Annual Meeting.